Discover key insights from Gilead Sciences' Q2 2025 earnings call, featuring Yeztugo's groundbreaking launch, upward guidance revisions, and strong ...

(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

Access is the central tenet to the success of lenacapavir as a form of preexposure prophylaxis (PrEP), according to Jeremiah Johnson, the executive director of PrEP4All and Mitchell Warren, the ...

CHICAGO — Chicago-area groups that support LGBTQ+ individuals are navigating an uncertain landscape while bracing for federal funding cuts that could affect HIV care and prevention.

Scientific breakthroughs are fueling new hope in women’s health. But experts warn that persistent gaps in funding and access could stall that progress.

In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don't require a daily oral pill and ...

A study on long-acting ART shows 92% viral suppression among HIV-1 viremia patients in the U.S. South, offering hope for high ...

Blacks and Hispanics are particularly affected by HIV, making up more than half (70 percent) of estimated new HIV infections ...

Healio received an APEX award for a 2024 report on the cloudy future of HIV vaccine research in the age of long-acting ...

Amidst limited doses, priority will be given to those at substantial risk of HIV acquisition, such as adolescent girls and young women who are engaged in marital or concurrent sexual partnerships." ...

Apretude (cabotegravir) – the first injectable type of HIV PrEP – was approved by the FDA in 2021, and is currently covered by Medicaid in Ohio. However, the drug is administered once every two months ...